Flow cytometric analysis of Human CD19 expression on human PBMC (human peripheral blood mononuclear cell). Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD3 antibody and SDT Biotin Mouse Anti- Human CD19 Antibody at 1.25 μl/test followed by Sav-PE. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | CD19 |
Synonyms | B-lymphocyte antigen CD19; LE-CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12 |
Location | Cell membrane |
Accession | P15391 |
Clone Number | S-R503-2 |
Antibody Type | Mouse mAb |
Isotype | IgG1 |
Application | FCM |
Reactivity | Hu |
Positive Sample | Human PBMC |
Purification | Protein G |
Concentration | 0.2 mg/ml |
Conjugation | Biotin |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
CD19 is a transmembrane glycoprotein and a member of the immunoglobulin superfamily, predominantly expressed on B lymphocytes, making it a significant marker for B cell development and function. It plays a crucial role in B cell activation, signal transduction, and growth regulation. CD19 is involved in the B cell receptor (BCR) signaling pathway, enhancing B cell activation thresholds and proliferation. In the context of disease, CD19 is highly expressed in most B cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B cell lymphomas, making it a promising target for immunotherapy. The CD19 molecule is also implicated in autoimmune and immunodeficiency disorders, with mutations in CD19 associated with severe immunodeficiency syndromes characterized by reduced antibody production.
Picture
Picture
FC
